Currently approved chimeric antigen receptor CAR-T cell therapies target CD-19 on B-cell acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.